Marina Biotech Completes Dosing of First Cohort in the Phase 1b/2a START-FAP Clinical Trial of CEQ508

Marina Biotech, Inc. MRNA today announced the completion of dosing for Cohort 1 in the Dose Escalation Phase of its START-FAP clinical trial with CEQ508. The first three patients received the starting dose of 1x10(8) colony forming units (cfu)/day for up to 28 days of continuous oral dosing. Patients were monitored by study staff on a daily basis with the primary study endpoint of determining safety and tolerability of CEQ508 in patients with FAP. Dosing of Cohort 2 is expected to begin in July 2011 with each patient in the cohort receiving a dose of 1x10(9) cfu/day for up to 28 days.